
Consumer Staples · Packaged Foods & Meats
$20.75
-0.22%
Vol: 5.0M
Friday, May 1, 2026
Campbell's reported Q2 earnings of $0.51, missing consensus of $0.568. Snacks segment down 6% with competitive pressure in chips. Management provided recovery roadmap (stabilize Q3, margin improvement Q4). Company closed Hyannis plant in April 2026 as part of snacks network optimization. Barclays, Morgan Stanley, UBS all cut PTs in March/April. Stock down 25.6% YTD.
The Campbell's Company reported Q2 fiscal 2026 earnings per share of $0.51, missing consensus of $0.568. Fiscal 2025 revenue was $10.25 billion (up 6.40% YoY) but recent earnings disappointed. Company appointed Joshua Levine as Chief Investor Relations Officer effective March 18, 2026. Stock down 25.6% year-to-date and 39.8% over past year at $20.62. Rao's brand surpassed $1 billion trailing twelve-month net sales. Core Meals & Beverages showed growth but Snacks segment declined 6% with margin hit. Consensus analyst rating is Hold with 12-month target of $26.41.
Campbell slid 3.44% pre-market to $23.83 USD on March 18 following March 11 earnings miss and annual sales/profit forecast reductions announced during Q2 FY2026 results. Stock down sharply from recent levels with after-hours recovery to $25.05 (up 1.50%) suggesting some stabilization. UBS maintains Sell rating; consensus Hold with $31.40 average target implies 39.93% upside if fundamentals stabilize.
Campbell's declined to $23.83 in pre-market (down -3.44%) following March 11 Q2 fiscal 2026 earnings miss with EPS of $0.51 missing forecast by 10.53%. Revenue of $2.6B fell short with Snacks segment margin compression of 390 basis points to 7%. UBS lowered price target to $20 maintaining Sell rating.
Campbell's Company reported a 3% plunge in fiscal Q2 organic sales with adjusted operating margin slipping 290bps to 11% due to inflation, causing shares to sink 6%. Full-year guidance was cut to a 1%-2% decline in sales with adjusted EPS of $2.15-$2.25, signaling a challenging consumer environment. UBS lowered its price target to $20 from $24 on March 13, 2026; J.P. Morgan maintains a Hold, and 15 analysts give an average "Hold" rating with a $31.40 target suggesting 40% upside but dependent on a consumer recovery.
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| CPBTHE | $20.75 | -0.22% | -5.6% | 9.5x | 0.03 | $6.2B |
| MDLZMONDELEZ | $61.40 | -0.07% | +5.2% | 18.3x | 0.39 | $78.9B |
| HSYHERSHEY | $182.63 | -1.68% | -10.7% | 18.8x | 0.17 | $37.6B |
| KHCKRAFT | $22.53 | -0.60% | -3.9% | 10.6x | 0.05 | $26.8B |
| TSNTYSON | $63.84 | -0.36% | -0.7% | 14.6x | 0.43 | $22.6B |
| GISGENERAL | $34.83 | -1.37% | -6.3% | 10.7x | — | $18.8B |
Price below 200d MA — bearish structure.